{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:25:06Z","timestamp":1791869106680,"version":"4.3.4"},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000982","name":"Conquer Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ijrobp.2024.11.099","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T22:14:19Z","timestamp":1734128059000},"page":"10-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Randomized Study of Consolidation Chemoradiotherapy Versus Observation After First-line Chemotherapy in Advanced Gallbladder Cancers: RACE-GB study"],"prefix":"10.1016","volume":"122","author":[{"given":"Sushma","family":"Agrawal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishwas","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Rahul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhakar","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajan","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2024.11.099_bib0001","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2024.11.099_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103328","article-title":"Chemotherapy for advanced gallbladder cancer (GBC): a systematic review and meta-analysis","volume":"163","author":"Azizi","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ijrobp.2024.11.099_bib0003","article-title":"SWOG S1815: a phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers","author":"Shroff","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.11.099_bib0004","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/jhbp.1219","article-title":"Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA)","volume":"30","author":"Ioka","year":"2023","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"10.1016\/j.ijrobp.2024.11.099_bib0005","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2024.11.099_bib0006","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S2468-1253(22)00043-7","article-title":"Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study","volume":"7","author":"Oh","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ijrobp.2024.11.099_bib0007","doi-asserted-by":"crossref","first-page":"577","DOI":"10.4103\/ijc.IJC_1145_20","article-title":"Consolidation chemoradiation (cCTRT) improves survival in responders to first-line chemotherapy (CT) in locally advanced gallbladder cancer (LA-GBC): A new standard of care?","volume":"59","author":"Alam","year":"2022","journal-title":"Indian J Cancer"},{"key":"10.1016\/j.ijrobp.2024.11.099_bib0008","doi-asserted-by":"crossref","first-page":"88","DOI":"10.18203\/2349-3259.ijct20230055","article-title":"A randomized study of consolidation chemo-radiotherapy versus observation after first-line chemotherapy in advanced gall bladder cancers (RACE-GB Study): trial protocol","volume":"10","author":"Agrawal","year":"2023","journal-title":"Int J Clin Trials"},{"key":"10.1016\/j.ijrobp.2024.11.099_bib0009","doi-asserted-by":"crossref","first-page":"955","DOI":"10.21873\/anticanres.11404","article-title":"Clinical target volume in biliary carcinoma: a systematic review of pathological studies","volume":"37","author":"Ilaria","year":"2017","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ijrobp.2024.11.099_bib0010","first-page":"1334","article-title":"Toxicity criteria of the radiation therapy oncology group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)","volume":"5","author":"Cox","year":"1995","journal-title":"Int J Radiation Oncology Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.11.099_bib0011","article-title":"Predictors of toxicity in a randomized study of consolidation chemoradiation vs observation after chemotherapy in advanced gall bladder cancers","volume":"9","author":"Agrawal","year":"2024","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2024.11.099_bib0012","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/annonc\/mdv249","article-title":"A standardized, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)","volume":"26","author":"Cherny","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2024.11.099_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5348\/ijhpd-2016-63-OA-19","article-title":"Gemcitabine and cisplatin in inoperable, loco-regionally advanced and metastatic gallbladder cancer: A study from Northern India cancer institute","author":"Talwar","year":"2017","journal-title":"Int J Hepatobiliary Pancreat Dis"},{"key":"10.1016\/j.ijrobp.2024.11.099_bib0014","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.21873\/anticanres.13445","article-title":"Radiotherapy or chemoradiation in unresectable biliary cancer: a retrospective study","volume":"39","author":"Bisello","year":"2019","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ijrobp.2024.11.099_bib0015","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00280-013-2340-5","article-title":"Efficacy of concurrent chemoradiotherapy with 5-fluorouracil or gemcitabine in locally advanced biliary tract cancer","volume":"73","author":"Yi","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ijrobp.2024.11.099_bib0016","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.21037\/jgo-20-245","article-title":"Chemoradiotherapy for patients with locally advanced or unresectable extra-hepatic biliary cancer","volume":"11","author":"Jethwa","year":"2020","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.ijrobp.2024.11.099_bib0017","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1440-1746.1997.tb00356.x","article-title":"Duodenal erosions and ulcers in patients with pancreato-biliary obstruction","volume":"12","author":"Abbas","year":"1997","journal-title":"Gastroenterol Hepatol (NY)"},{"key":"10.1016\/j.ijrobp.2024.11.099_bib0018","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/jhbp.712","article-title":"Role of positron emission tomography-contrast enhanced computed tomography in locally advanced gallbladder cancer","volume":"27","author":"Patkar","year":"2020","journal-title":"J Hepatobiliary Pancreat Sci"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301624037064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301624037064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T22:50:33Z","timestamp":1762296633000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301624037064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0360301624037064"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2024.11.099","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Randomized Study of Consolidation Chemoradiotherapy Versus Observation After First-line Chemotherapy in Advanced Gallbladder Cancers: RACE-GB study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2024.11.099","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}